Cargando…
Understanding noninferiority trials
Noninferiority trials test whether a new experimental treatment is not unacceptably less efficacious than an active control treatment already in use. With continuous improvements in health technologies, standard care, and clinical outcomes, the incremental benefits of newly developed treatments may...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Pediatric Society
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3510268/ https://www.ncbi.nlm.nih.gov/pubmed/23227058 http://dx.doi.org/10.3345/kjp.2012.55.11.403 |
_version_ | 1782251445984165888 |
---|---|
author | Hahn, Seokyung |
author_facet | Hahn, Seokyung |
author_sort | Hahn, Seokyung |
collection | PubMed |
description | Noninferiority trials test whether a new experimental treatment is not unacceptably less efficacious than an active control treatment already in use. With continuous improvements in health technologies, standard care, and clinical outcomes, the incremental benefits of newly developed treatments may be only marginal over existing treatments. Sometimes assigning patients to a placebo is unethical. In such circumstances, there has been increasing emphasis on the use of noninferiority trial designs. Noninferiority trials are more complex to design, conduct, and interpret than typical superiority trials. This paper reviews the concept of noninferiority trials and discusses some important issues related to them. |
format | Online Article Text |
id | pubmed-3510268 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | The Korean Pediatric Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-35102682012-12-07 Understanding noninferiority trials Hahn, Seokyung Korean J Pediatr Review Article Noninferiority trials test whether a new experimental treatment is not unacceptably less efficacious than an active control treatment already in use. With continuous improvements in health technologies, standard care, and clinical outcomes, the incremental benefits of newly developed treatments may be only marginal over existing treatments. Sometimes assigning patients to a placebo is unethical. In such circumstances, there has been increasing emphasis on the use of noninferiority trial designs. Noninferiority trials are more complex to design, conduct, and interpret than typical superiority trials. This paper reviews the concept of noninferiority trials and discusses some important issues related to them. The Korean Pediatric Society 2012-11 2012-11-23 /pmc/articles/PMC3510268/ /pubmed/23227058 http://dx.doi.org/10.3345/kjp.2012.55.11.403 Text en Copyright © 2012 by The Korean Pediatric Society http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Hahn, Seokyung Understanding noninferiority trials |
title | Understanding noninferiority trials |
title_full | Understanding noninferiority trials |
title_fullStr | Understanding noninferiority trials |
title_full_unstemmed | Understanding noninferiority trials |
title_short | Understanding noninferiority trials |
title_sort | understanding noninferiority trials |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3510268/ https://www.ncbi.nlm.nih.gov/pubmed/23227058 http://dx.doi.org/10.3345/kjp.2012.55.11.403 |
work_keys_str_mv | AT hahnseokyung understandingnoninferioritytrials |